Semaglutide vs. Tirzepatide for Weight Loss in Miami: How They Differ and Which One Fits Your Goals

2026-04-01 | Weight Loss

Medically reviewed by Dr. Lourdes Bosch, Medical Director, ILU Collective

Medical weight loss has changed significantly with the introduction of GLP-1 receptor agonists. Two medications now dominate the conversation: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound). Both are injectable medications that support meaningful weight loss when combined with diet and exercise - but they are not the same drug, they do not work the same way, and the right choice depends on your health profile. At ILU Collective in Coral Gables, the medical weight loss protocol is physician-supervised and individualized because a one-size-fits-all approach to these medications does not produce the best outcomes.

How Semaglutide Works: The GLP-1 Receptor Agonist

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone naturally produced in the gut after eating. It signals the brain to register satiety, slows gastric emptying (the rate at which food leaves the stomach), and stimulates insulin secretion in response to elevated blood sugar.

Semaglutide mimics this natural hormone but at a level and duration that the body does not produce on its own. The result is a sustained reduction in appetite and caloric intake. Patients on semaglutide consistently report feeling full sooner, thinking about food less frequently, and finding it easier to make portion-controlled choices - not through willpower, but through a genuine reduction in hunger signaling.

The STEP clinical trial program (Semaglutide Treatment Effect in People with Obesity) demonstrated an average weight loss of approximately 15 percent of body weight over 68 weeks in participants receiving semaglutide 2.4 mg weekly alongside lifestyle intervention. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Semaglutide is administered as a once-weekly subcutaneous injection. Dosing typically starts low (0.25 mg weekly) and increases gradually over several months to minimize gastrointestinal side effects. The most common side effects include nausea, vomiting, diarrhea, and constipation - most of which diminish as the body adjusts to each dose level. Individual results vary.

How Tirzepatide Works: The Dual GIP/GLP-1 Receptor Agonist

Tirzepatide is a dual-action medication. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism is what distinguishes it from semaglutide and every other medication currently available for weight management.

GIP is another incretin hormone produced in the gut. Like GLP-1, it stimulates insulin secretion and plays a role in glucose metabolism. But GIP also appears to have additional effects on fat tissue metabolism and energy expenditure that GLP-1 alone does not replicate. The combination of GLP-1 and GIP receptor activation produces appetite suppression, slowed gastric emptying, improved insulin sensitivity, and potentially enhanced fat mobilization.

The SURMOUNT clinical trial program demonstrated an average weight loss of approximately 20 to 22.5 percent of body weight over 72 weeks in participants receiving tirzepatide at the highest dose (15 mg weekly) alongside lifestyle intervention. Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Tirzepatide is also administered as a once-weekly subcutaneous injection. Dosing starts at 2.5 mg and increases gradually. Side effects are similar to semaglutide - nausea, diarrhea, constipation, and decreased appetite are the most commonly reported. The gradual dose escalation protocol helps manage these effects. Individual results vary.

Head-to-Head: Key Differences That Matter Clinically

Mechanism of action: Semaglutide activates one receptor (GLP-1). Tirzepatide activates two receptors (GLP-1 and GIP). The dual mechanism may account for the greater average weight loss observed in tirzepatide clinical trials compared to semaglutide clinical trials - though direct head-to-head comparison data is still being developed.

Average weight loss: Clinical trials showed approximately 15 percent average body weight loss with semaglutide (STEP trials) and approximately 20 to 22.5 percent with tirzepatide at the highest dose (SURMOUNT trials). These are averages across large study populations - individual results vary significantly based on starting weight, dose, adherence, diet, and exercise.

Dosing schedule: Both are once-weekly injections. Semaglutide titrates from 0.25 mg to a target dose of 2.4 mg. Tirzepatide titrates from 2.5 mg to a target dose of 5 mg, 10 mg, or 15 mg depending on response and tolerability.

Side effect profiles: Both medications share a similar gastrointestinal side effect profile. Nausea is the most common complaint during dose escalation for both. Some patients tolerate one medication better than the other - this is individual and cannot be predicted before starting treatment. Physician supervision during dose escalation is important for managing side effects and adjusting the protocol as needed.

FDA approval status: Both semaglutide (as Wegovy) and tirzepatide (as Zepbound) are FDA-approved for chronic weight management. Both are also available in formulations approved for type 2 diabetes management (Ozempic and Mounjaro, respectively). The weight management indication requires a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity.

Why Physician Supervision Changes the Outcome

These medications are not supplements. They are prescription pharmaceuticals with real physiological effects that require clinical monitoring. The patients who achieve the best, most sustainable results are those whose treatment is managed by a physician who adjusts dosing based on response, monitors for side effects, and integrates the medication into a broader health protocol.

At ILU Collective, the medical weight loss protocol under Dr. Lourdes Bosch includes initial health assessment and lab work, individualized medication selection (semaglutide or tirzepatide based on your health profile and goals), structured dose escalation with regular check-ins, nutritional guidance to support the metabolic changes the medication produces, and monitoring for side effects and metabolic markers throughout treatment.

The physician-supervised advantage is not just safety - though that matters. It is the clinical judgment to know when to hold a dose increase because of side effects, when to switch medications because response has plateaued, and when to adjust the supporting protocol because the patient's metabolic needs have changed. This level of management is not available through telehealth-only weight loss services or online prescription platforms.

Learn more about ILU's medical weight loss approach at our Weight Loss page and our Semaglutide page.

ILU Collective's Medical Weight Loss Protocol in Coral Gables

The weight loss protocol at ILU Collective is designed around the reality that medication alone does not produce sustainable results. The protocol includes the medication as a central component, but it also addresses the behavioral, nutritional, and metabolic factors that determine whether weight loss is maintained after the active treatment phase.

Initial consultation includes a comprehensive health assessment, body composition analysis, metabolic lab work, and a review of your weight history and prior weight loss attempts. This information drives the medication selection - not every patient is best served by the same drug at the same dose.

During the active treatment phase, patients visit ILU Collective regularly for medication administration, weight and body composition tracking, side effect management, and protocol adjustments. Many patients in the medical weight loss program also pursue complementary treatments at ILU - IV therapy for hydration and nutrient support, body contouring for skin tightening as weight decreases, or injectable treatments as facial volume changes become apparent during significant weight loss.

The integration of medical weight loss with aesthetic medicine is one of the unique advantages of pursuing this protocol at a physician-supervised med spa rather than a standalone weight loss clinic. As your body changes, the clinical team can address the aesthetic implications of that change in real time. Explore complementary treatments at our Body Contouring page and our IV Therapy page.

What to Expect: Timeline and Realistic Results

Most patients begin to notice appetite changes within the first 1 to 2 weeks of treatment. Measurable weight loss typically begins during the dose escalation phase and accelerates as the target dose is reached.

The first 3 months represent the most rapid phase of weight loss for most patients. Months 4 through 12 typically show continued but more gradual loss as the body adapts. The total duration of treatment varies - some patients achieve their goal within 6 months, others require 12 months or longer.

Sustainability is the real question. Clinical data shows that patients who discontinue GLP-1 medications without a maintenance protocol regain a significant portion of lost weight within 12 months. At ILU Collective, the transition plan - including dose tapering, metabolic monitoring, and lifestyle reinforcement - is built into the protocol from the beginning. The goal is not just weight loss. It is a new metabolic baseline that can be maintained.

ILU Collective offers a GLP-1 Wellness Membership for patients pursuing medical weight loss. See our Memberships page for details. Individual results vary based on starting weight, medication, dose, adherence, diet, exercise, and overall health status.

Medical Disclaimer: Medical weight loss treatments at ILU Collective are performed under the supervision of Dr. Lourdes Bosch, Medical Director, under Florida Statute 458.3265. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in eligible adults. These are prescription medications with potential side effects and contraindications. Individual results vary. This content is for educational purposes only and does not constitute medical advice. Schedule a consultation to discuss whether medical weight loss is appropriate for your health goals. Contact ILU Collective at (786) 539-3085.

Book a Consultation at ILU Collective